Dubai: An Emirati woman is now living cancer-free following the early detection of a genetic mutation that indicated a risk of thyroid cancer, a case that showcases the potential of precision medicine.

The breakthrough was made possible through her participation in the Emirati Genome Programme (EGP), one of the world’s largest population genomics initiatives, aimed at predicting and preventing genetic diseases among Emiratis.

Hasan Jasem Al Nowais, Managing Director and Group CEO of M42, which oversees the EGP, confirmed that genome sequencing on the 40-year-old participant revealed a significant mutation in genes that could lead to the development of cancer.

"She didn’t have cancer.

She was going to develop cancer through that gene that’s going to mutate to become cancerous," Al Nowais stated during a press briefing at the Arab Health exhibition in Dubai.

Upon the discovery, the medical team acted swiftly, performing a thyroidectomy to remove the at-risk gland.

"When diagnosed, they confirmed 100 percent that this gene was mutating to develop thyroid cancer," Al Nowais added, noting the importance of early detection and preventive care.

The EGP aims to collect genetic samples from a target of one million Emiratis, analyzing around 8 milliliters of blood from adults or two cheek swabs from children.

The program's goal is to understand the prevalence of genetic diseases, the types of genetic mutations present, and to innovate effective healthcare plans for prevention.

In related developments, M42 has signed a memorandum of understanding with Uzbekistan’s Ministry of Health to enhance genomic research and collaboration in healthcare, a move expected to improve care for the Uzbek population and diversify global genomic research efforts.

Al Nowais emphasized the benefits of including underrepresented populations in genomic studies to enhance clinical care and disease detection capabilities worldwide.

In addition, M42 is expanding its reach in the healthcare sector applying advanced technologies.

The organization has acquired Diaverum, a leader in renal care, and plans to bring its services to Abu Dhabi and Al Ain.

Furthermore, M42 has partnered with Rhapsody, a digital health platform, to support precision medicine initiatives using Microsoft Azure, aiming for more efficient data management in healthcare.

The Arab Health exhibition in Dubai also featured discussions on the rising trend of robotic-assisted surgeries (RAS) in the UAE.

Dr. Jado Kamal from American Hospital Dubai shared that the hospital has performed over 2,000 robotic surgeries since 2020, contributing significantly to improved surgical outcomes through minimally invasive techniques.

Dr. Shafik Sidani from Cleveland Clinic Abu Dhabi detailed the transformative impact of robotic methods in complex procedures such as organ transplants, stating that these techniques have enabled significant advancements in surgical capabilities.

The Digestive Disease Institute reported more than 400 robotic surgical cases in 2024 alone, demonstrating a considerable shift in surgical practice within the region.

As the demand for robotic surgery continues to rise, Burjeel Medical City is also expanding its robotic surgical team rapidly.

Dr. Jafaru Abu noted that, beginning with one certified surgeon, the hospital now has over 15 robotic surgeons trained to handle complex surgical cases, with a target of completing around 1,000 robotic cases by the end of 2025.

These developments reflect substantial progress in the UAE’s healthcare sector, particularly in precision medicine and robotic surgical techniques, underscoring the country's commitment to enhancing patient care through innovative technologies.